Listed biotech stocks may have fallen from grace, but large investors’ appetite for life sciences is un-sated. In the last six months, private equity (PE) players have bought or teamed up with three European-based venture capital (VC) firms in a bid to expand their life sciences expertise and holdings – and grab some of the out-sized returns enjoyed by earlier-stage investors over the last few years.
Bigger Money: Private Equity Grabs European VC
Deals show large investors’ appetite for early-stage biotech, but can VC and PE rub along?
More from Business Strategy
More from In Vivo
• By
Crystal Qin has led LaNova Medicines’ swift rise in the biotech world through strategic partnerships and innovative R&D, highlighted by a record deal with big pharma.
• By
In Vivo Rising Leader Amir Hefni, CEO of Resolution Therapeutics, discusses the company's advancements in macrophage cell therapies for inflammatory and fibrotic diseases, and his transition from big pharma to biotech leadership.
• By
The sixth annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.